跳轉至內容
Merck
全部照片(1)

文件

M2300000

米诺地尔

European Pharmacopoeia (EP) Reference Standard

同義詞:

6-(1-哌啶基)-2,4-嘧啶二胺 3-氧化物, 6-(1-哌啶基)嘧啶-2,4-二胺 3-氧化物

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C9H15N5O
CAS號碼:
分子量::
209.25
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

minoxidil

製造商/商標名

EDQM

mp

272-274 °C (dec.) (lit.)

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

NC1=CC(=NC(=N)N1O)N2CCCCC2

InChI

1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6,11,15H,1-5,10H2

InChI 密鑰

ZIMGGGWCDYVHOY-UHFFFAOYSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Minoxidil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

激活 ATP 激活的 K+ 通道;血管扩张剂;减缓或停止脱发,促进头发再生。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Exclamation mark

訊號詞

Warning

危險分類

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3


Choose from one of the most recent versions:

分析證明 (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

E J van Zuuren et al.
The British journal of dermatology, 167(5), 995-1010 (2012-10-09)
Female pattern hair loss (FPHL) or androgenic alopecia is the most common type of hair loss affecting women with reduced hair density and can have a serious psychological impact. It is characterized by progressive replacement of slow cycling terminal hair
Esther J van Zuuren et al.
The Cochrane database of systematic reviews, 5(5), CD007628-CD007628 (2012-05-18)
Female pattern hair loss, or androgenic alopecia, is the most common type of hair loss affecting women. It is characterised by progressive shortening of the duration of the growth phase of the hair with successive hair cycles, and progressive follicular
Natasha Atanaskova Mesinkovska et al.
Dermatologic clinics, 31(1), 119-127 (2012-11-20)
Female pattern hair loss (FPHL) is the most common cause of alopecia in women. FPHL is characterized histologically with increased numbers of miniaturized, velluslike hair follicles. The goal of treatment of FPHL is to arrest hair loss progression and stimulate
Chester L Bowen et al.
Bioanalysis, 4(23), 2823-2832 (2012-12-12)
Stabilization of phase II metabolites is an important consideration during bioanalytical method development, method validation and sample analysis. Generic approaches to stabilize these metabolites during storage in liquid-based matrices include pH adjustment of samples prior to storage and/or temperature control;
Soung-Hoon Lee et al.
PloS one, 7(4), e34152-e34152 (2012-04-17)
Alopecia is the common hair loss problem that can affect many people. However, current therapies for treatment of alopecia are limited by low efficacy and potentially undesirable side effects. We have identified a new function for valproic acid (VPA), a

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務